The Gist
Markets
Currencies Rates & Bonds Equities Economy
Wealth
Investment Tips Fine Living Retirement
Webinars
webinar-thumb-1108
Estate Planning: Building a Legacy for the Future 
November 8, 2022
Webinar-mobile-desktop-267x320-1
Outlook 2022: Recover. Restart. Rebalance.
March 31, 2022
Thumbnail - Diversify Across the Globe with the Metro$ World Equity Feeder Fund
Diversify Across the Globe with the Metro$ World Equity Feeder Fund
November 23, 2021
View All Webinars
Portfolio Picks
Bonds Stocks
Downloads
bonds-ss-1
Consensus Pricing – March 23, 2023
March 24, 2023
investment-ss-5
Consensus Pricing – March 10, 2023
March 10, 2023
investment-ss-3
Metrobank Economic Updates for March 2023
March 10, 2023
View all Reports
Visit us at metrobank.com.ph Contact Us
Follow us on our platforms.

How may we help you?

TOP SEARCHES
TRENDING ARTICLES

Login

Access Exclusive Content
Login to Wealth Manager
Economy 1 MIN READ

BRIEF-Shanghai Henlius Biotech Announces License Agreement With Getz Pharma For Rights Of Handayuan

February 23, 2022By Reuters
Related Articles
UPDATE 2-Philippine leader Duterte's preferred successor quits presidential race November 30, 2021 CORRECTED-Bitcoin resumes tumble, drops around 2% May 12, 2022 S&P posts 4th straight decline amid recession talk December 6, 2022

Feb 23 (Reuters) – Shanghai Henlius Biotech Inc 2696.HK:

  • ANNOUNCES LICENSE AGREEMENT WITH GETZ PHARMA FOR RIGHTS OF HANDAYUAN

  • TO GRANT LICENSE TO GETZ PHARMA TO COMMERCIALISE ADALIMUMAB INJECTION IN PAKISTAN, PHILIPPINES, AMONG OTHER COUNTRIES

Further company coverage: 2696.HK

((Reuters.Briefs@thomsonreuters.com;))

This article originally appeared on reuters.com

Read More Articles About:
Worldwide News Philippine News Rates & Bonds Equities Economy Investment Tips Fine Living